-
Neuronetics Wins A Sell-Side Bull With Pill-Free Depression Treatment
Monday, July 23, 2018 - 4:58pm | 320Read More...Neuronetics Inc (NASDAQ: STIM) boasts a therapy that addresses a pressing medical need, according to JMP Securities. The Analyst Analyst David Turkaly initiated coverage of Neuronetics with an Outperform rating and $36 price target. The Thesis For patients who have failed one of...
-
Believe In The Haemonetics Turnaround Story; JMP Upgrades To Market Outperform
Thursday, July 13, 2017 - 12:58pm | 333Read More...Shares of Haemonetics Corporation (NYSE: HAE), a provider of products to customers involved in the processing, handling and analysis of blood, gained more than 4 percent Thursday morning after analysts at JMP Securities turned bullish on the stock. David Turkaly upgraded Haemonetics' stock from...
-
UPDATE: JMP Securities Reiterates On STERIS Corp Following Company HQ Visit
Tuesday, September 9, 2014 - 9:01am | 219Read More...In a report published Tuesday, JMP Securities analyst David Turkaly reiterated a Market Outperform rating on STERIS Corp (NYSE: STE), and raised the price target from $58.00 to $65.00. In the report, JMP Securities noted, “The stock has had a solid run (+~19% YTD), and no longer screens as a value...
